NCT05378503 - Phase IV Study of Qsymia in Obese Patients | Biotech Hunter

Enrollment

232

Participants

Timeline

Start Date

September 17, 2021

Primary Completion Date

October 30, 2023

Study Completion Date

October 30, 2023

Conditions

Obesity

Interventions

DRUG

Qsymia 3.75Mg-23Mg Extended Release Capsule

From W0 to W2, once a daily.

DRUG

Qsymia 7.5Mg-46Mg Extended Release Capsule

"1. From W2 to W14, once a daily.~2. At W14, if the weight loss rate is 3% or more, from W14 to W56(the end of visit), once a daily."

DRUG

Qsymia 11.25Mg-69Mg Extended Release Capsule

At W14, if the weight loss rate is NOT 3% or more, from W14 to W16, once a daily.

DRUG

Qsymia 15Mg-92Mg Extended Release Capsule

At W14, if the weight loss rate is NOT 3% or more, from W16 to W56(the end of visit), once a daily.

DRUG

Placebo

From W0(Randomisation) to W56(the End of visit) once a daily.

Trial Locations (8)

Hanyang Univ. Guri Hospital, Guri-si

The Catholic Univ. of Korea Bucheon St. Mary's Hospital, Bucheon-si

Sejong Hospital, Bucheon-si

Gil Hospital, Incheon

GangNeung Asan Hospital, Gangneung

KyungHee Univ. Hospital, Seoul

KyungHee Univ. Hospital at Gangdong, Seoul

Severance Hospital, Seoul